UltraSight Raised $24 Million for AI Ultrasound

The company secured new funding to expand its AI-guided cardiac ultrasound platform in the United States.

Updated on Sept. 23, 2026 in Healthcare

Bold flat-color editorial illustration showing a stylized ultrasound transducer, representing advanced medical technology investment.
UltraSight, an AI-guided cardiac ultrasound developer, secured $24 million in Series B2 funding to accelerate adoption of its technology across U.S. health systems. AI Illustration. Upload story photo >

Live Poll

Would you trust a medical diagnosis if performed by AI-guided ultrasound rather than a human specialist?

UltraSight has raised $24 million in a Series B2 financing round led by the Alive HealthTech Growth Fund. The firm intends to use the capital to increase the adoption of its AI-guided cardiac ultrasound Echosystem across health systems nationwide.

Why it matters

By providing real-time AI guidance for echocardiography, the technology aims to address critical healthcare workforce shortages. This support allows clinicians to perform imaging more effectively in intensive care and other urgent settings.

UltraSight secured $24 million in Series B2 financing, bringing its platform to more than 10 commercial sites currently in operation. Independent research published in JAMA Cardiology indicated 93% sensitivity and 96% specificity for novice operators using the tools.

The players

UltraSight

This health technology company develops AI-driven solutions to assist clinicians with cardiac ultrasound procedures.

Rick Geoffrion

He is a veteran executive with 30 years of industry experience who was recently appointed as the chairman of the UltraSight board.

Alive HealthTech Growth Fund

This investment firm acted as the lead investor for the company's recent Series B2 financing round.

The details

The UltraSight Echosystem combines specialized training, real-time AI guidance, and analytics to assist medical professionals in performing cardiac ultrasounds. The company has also reorganized its leadership, appointing Rick Geoffrion as board chairman while adding Tal Wenderow and Barak Ben-Eliezer to the board.

Timeline

  1. UltraSight announced the $24 million funding round on September 23, 2026.

Market Landscape

The move aligns with the broader integration of AI diagnostics into clinical practice to bridge gaps created by physician and sonographer shortages. UltraSight is positioning its software to become a standard tool in intensive care units where rapid decision-making is vital for patient outcomes.

Clinicians and hospital systems may gain access to more efficient diagnostic tools designed to simplify the ultrasound process for non-specialist staff. This could lead to faster imaging turnaround times for patients undergoing care in intensive or urgent settings.

The takeaway

The investment underscores a growing trend toward using AI to democratize complex medical imaging procedures. This shift highlights a strategic move to prioritize efficiency and diagnostic accuracy in high-pressure clinical environments.

Further reading

Learn more about the latest innovations in Healthcare affecting clinical practice.

Live Poll

Would you trust a medical diagnosis if performed by AI-guided ultrasound rather than a human specialist?